A new FDA rule that would govern off-label marketing has drugmakers in a minor tizzy—and they're demanding that the agency set its change aside.

Sanofi and Swiss contractor Lonza will share the cost of building a €270 million ($286.3 million) plant to expand capacity for new biologic meds.

Seeing is believing. And Regeneron Pharmaceuticals wants people to “see” what it’s like to have retinal disease.

Masking depression is never a good idea. Otsuka and Lundbeck are back on the air to make that case with a new TV ad for antipsychotic Rexulti.

The market for hepatitis C drugs is shrinking. Shortly after spending $3.9 billion on Idenix, Merck is taking a $2.9 billion hit on an experimental compound.

For years, Big Pharma has utilized the help of academic experts at Precision Health Economics to carry their message that groundbreaking treatments demand high…

Novartis isn’t letting its crosstown rival get all the regulatory attention when it comes to ALK+ metastatic non-small cell lung cancer.

China updated national drug list with some blockbuster Western meds, Daiichi and ArQule’s tivantinib failed another trial, Dr. Reddy's got an FDA Form 483.